Apr 19, 2025, 19:18

American Cancer Society Institutional Research Grants

Institutional Research Grants (IRG) are awarded to eligible institutions as block grants to provide seed funding for newly independent investigators to launch cancer research projects. These funds enable junior faculty to generate preliminary data that will help them successfully compete for national-level research grants. Each institution selects recipients internally through an IRG review committee.

Eligibility Criteria

Must hold the rank of Associate or Full Professor at a US academic institution
Must demonstrate a track record of peer-reviewed cancer research funding and publications
Must have experience mentoring junior investigators
Must have administrative or leadership experience (e.g., program or department chair)
Institution must have a strong cancer research program and qualified junior faculty pool

Funding Details

New IRGs: 120,000 USD per year for 4 years (total 480,000 USD)
Funds are used to award 3–6 pilot grants annually per institution
Each pilot grant must be between 20,000 and 60,000 USD
Year-to-year variation in pilot numbers and amounts is allowed
Renewal IRGs: 100,000 USD per year for 4 years (total 400,000 USD)
Renewal applications require at least 80,000 USD in institutional supplementation over 4 years
Separate application required for renewals in ProposalCentral

Further Information

Visit the American Cancer Society Research Grants Portal for submission details and eligibility support. Applications are submitted via ProposalCentral.

American Cancer Society block grants cancer cancer innovation cancer research institutions cancer seed funding Early-career researchers faculty grants institutional funding Institutional Research Grants IRG OncoDaily Oncology pilot grants

King Albert II’s Brave Battle: A Decade of Fighting Skin Cancer

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification